168 related articles for article (PubMed ID: 33780301)
1. The Effect of Market Competition on the Price of Topical Eye Drops.
Watane A; Kalavar M; Reyes J; Yannuzzi NA; Sridhar J
Semin Ophthalmol; 2022 Jan; 37(1):42-48. PubMed ID: 33780301
[TBL] [Abstract][Full Text] [Related]
2. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
Li DG; Joyce C; Mostaghimi A
JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
[TBL] [Abstract][Full Text] [Related]
3. Increased topical generic prices by manufacturers.
Bhatt MD; Bhatt BD; Dorrian JT; McLellan BN
J Am Acad Dermatol; 2019 May; 80(5):1353-1357. PubMed ID: 29544742
[TBL] [Abstract][Full Text] [Related]
4. Trends in Pricing and Generic Competition Within the Oral Antibiotic Drug Market in the United States.
Alpern JD; Zhang L; Stauffer WM; Kesselheim AS
Clin Infect Dis; 2017 Nov; 65(11):1848-1852. PubMed ID: 29020146
[TBL] [Abstract][Full Text] [Related]
5. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
[TBL] [Abstract][Full Text] [Related]
6. [Changes in the types and daily treatment costs of anti-glaucoma eye drops in China in recent 15 years].
Jia XF; Wu LL
Zhonghua Yan Ke Za Zhi; 2022 Nov; 58(11):890-895. PubMed ID: 36348525
[No Abstract] [Full Text] [Related]
7. Variation in Number of Doses, Bottle Volume, and Calculated Yearly Cost of Generic and Branded Latanoprost for Glaucoma.
Queen JH; Feldman RM; Lee DA
Am J Ophthalmol; 2016 Mar; 163():70-74.e1. PubMed ID: 26596398
[TBL] [Abstract][Full Text] [Related]
8. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
Hong SH; Shepherd MD; Scoones D; Wan TT
J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
[TBL] [Abstract][Full Text] [Related]
9. Impact of European pharmaceutical price regulation on generic price competition: a review.
Puig-Junoy J
Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
[TBL] [Abstract][Full Text] [Related]
10. Trends and determinants of retail prescription drug costs.
Teasdale B; Nguyen A; van Meijgaard J; Schulman KA
Health Serv Res; 2022 Jun; 57(3):548-556. PubMed ID: 35211965
[TBL] [Abstract][Full Text] [Related]
11. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
[TBL] [Abstract][Full Text] [Related]
12. Prescribing Patterns and Costs Associated with Postoperative Eye Drop Use in Medicare Beneficiaries Undergoing Cataract Surgery.
Zafar S; Wang P; Schein OD; Srikumaran D; Makary M; Woreta FA
Ophthalmology; 2020 May; 127(5):573-581. PubMed ID: 31952884
[TBL] [Abstract][Full Text] [Related]
13. Optimal price regulations in international pharmaceutical markets with generic competition.
Geng D; Saggi K
J Health Econ; 2020 May; 71():102315. PubMed ID: 32273046
[TBL] [Abstract][Full Text] [Related]
14. [Competition between branded and generic drugs in Austria: evidence from the market for ACE inhibitors].
Mahlich JC; Stadler I
Gesundheitswesen; 2012 Jan; 74(1):23-8. PubMed ID: 21154203
[TBL] [Abstract][Full Text] [Related]
15. Fill levels, cost comparisons, and expulsion force requirements of commonly used topical ophthalmic nonsteroidal anti-inflammatory drugs.
Heath M; McDonald MC; Murphy DA; Shah SV; Shah S; Ding K; Riaz KM
J Cataract Refract Surg; 2023 Jul; 49(7):747-753. PubMed ID: 36853852
[TBL] [Abstract][Full Text] [Related]
16. Do pharmaceutical prices rise anticipating branded competition?
Ellyson AM; Basu A
Health Econ; 2021 May; 30(5):1070-1081. PubMed ID: 33684255
[TBL] [Abstract][Full Text] [Related]
17. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
18. The impact of generic goods in the pharmaceutical industry.
Ferrándiz JM
Health Econ; 1999 Nov; 8(7):599-612. PubMed ID: 10544326
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of annual cost between brand and generic ocular beta-adrenergic blockers].
Ikeda H; Tsukamoto H; Sawa A; Sugimoto A; Mishima H; Kihira K
Yakugaku Zasshi; 2005 May; 125(5):463-7. PubMed ID: 15863979
[TBL] [Abstract][Full Text] [Related]
20. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
